A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Jean‐Luc Harousseau, Lars Möllgård, Alan K. Burnett et al.|Blood|2009

Cited by 146